Patent expiration risks for total worldwide prescription drug revenue 2010-2024

This statistic depicts the total prescription drug revenue worldwide that is at risk due to patent expiration from 2010 to 2024. In 2022, the industry is expected to have 40 billion U.S. dollars in prescription drug sales worldwide at risk due to patent expiration. After the expiration of patent protection, other companies are allowed to make cheaper generics of the originally branded drug.

Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

June 2019



Survey time period

as of May 2019

Supplementary notes

‘Total Sales at Risk’ represents the worldwide product sales in the year prior to patent expiry but allocated to the year of expiry. E.g. Plavix had sales of $7.1bn in 2011, this is shown as ‘At Risk’ in 2012.
* Projected.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 / Month *
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Pharmaceutical market worldwide"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.